Marinomed Biotech AG banner

Intrinsic Value

The intrinsic value of Marinomed Biotech AG (MARI) under the Base Case is 24.18 EUR per share. Compared with the current market price of 4 EUR, the stock appears Undervalued by 83% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

MARI Intrinsic Value
€24.18
Undervaluation 83%
Intrinsic Value
Price €4
Alert me when MARI is below its intrinsic value
Today €19.34 · Already reached, the price is 79.3% below it

MARI is cheaper than usual. It was this cheap or cheaper on less than 1% of days in the past 5 years.

Alternatives to MARI

Fundamental Analysis

What Marinomed Biotech Does

Pharmaceuticals Health Care

Marinomed Biotech AG is an Austrian specialty biotech company that develops and sells medicines and medical products for respiratory and eye conditions. Its best-known products are based on two technology platforms: Carragelose, a seaweed-derived antiviral ingredient used in nasal sprays and throat products, and Marinosolv, a formulation technology designed to make hard-to-dissolve drug compounds easier to use in eye and allergy treatments.

Headquarters
Austria AT
Employees
32
IPO date
Feb 1, 2019
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Marinomed Biotech AG

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue MARI Research

Decided on Marinomed Biotech? Get an email when MARI reaches the price you’d buy at. Free with an account.

Other Marinomed Biotech listings

What is the Intrinsic Value of one MARI stock?

The intrinsic value for Marinomed Biotech AG (MARI) under the Base Case is 24.18 EUR.

Is MARI stock undervalued or overvalued?

Compared with the current market price of 4 EUR, the stock appears Undervalued by 83% .

How reliable are our estimates? See how past valuations played out
Back to Top